{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:58:48Z","timestamp":1785405528608,"version":"3.56.0"},"reference-count":63,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mays Family Cancer Center at University of Texas Health San Antonio","award":["P30 CA054174"],"award-info":[{"award-number":["P30 CA054174"]}]},{"award":["P30 CA054174"],"award-info":[{"award-number":["P30 CA054174"]}],"id":[{"id":"https:\/\/ror.org\/02f6dcw23","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Roger L. and Laura D. Zeller Charitable Foundation Chair in Urologic Cancer"},{"name":"Glenda and Gary Woods Distinguished Chair in GU Oncology"},{"name":"Max & Minnie Tomerlin Voelcker Fund"},{"id":[{"id":"https:\/\/ror.org\/00951b249","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"CDMRP","doi-asserted-by":"publisher","award":["CA170270\/P1P2"],"award-info":[{"award-number":["CA170270\/P1P2"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BCa Advocacy Network"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention & Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170345"],"award-info":[{"award-number":["RP170345"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"award":["RP170345"],"award-info":[{"award-number":["RP170345"]}],"id":[{"id":"https:\/\/ror.org\/0003xa228","id-type":"ROR","asserted-by":"publisher"}]},{"name":"MSTP Program","award":["NIH T32GM113896"],"award-info":[{"award-number":["NIH T32GM113896"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Bladder cancer (BCa) is characterized by frequent recurrence and limited durable responses to immunotherapy, in part due to poor T-cell infiltration into tumors. While the chemokine CCL2 and its receptor CCR2 have traditionally been associated with recruitment of immunosuppressive myeloid cells and tumor promotion, we reveal an unexpected anti-tumor role for this pathway in BCa. Methods: Using orthotopic and carcinogen-induced murine BCa models, we demonstrate that genetic deletion or antibody blockade of CCL2 or CCR2 accelerates tumor progression, reduces intratumoral CD4+ and CD8+ T-cell infiltration, and shortens survival. Results: Mechanistic studies show that CCL2 promotes recruitment of CCR2+ effector T cells with enhanced activation and cytotoxicity. Mixed bone marrow chimeras, T-cell-specific CCR2 knockouts, and adoptive transfers confirm that CCR2 signaling within T cells is essential for their trafficking and anti-tumor function. In human BCa, CCL2 expression is reduced in tumors compared to adjacent urothelium, correlating with diminished T-cell infiltration. Importantly, high tumor CCL2 levels are associated with improved recurrence-free survival in patients with BCa. To therapeutically leverage this pathway, we developed a novel intravesical recombinant CCL2 (rCCL2) approach. rCCL2 delivery significantly increased CCR2+ T-cell infiltration, reduced tumor burden, and extended survival in both syngeneic MB49 and double-humanized patient-derived xenograft (PDX) BCa models. Conclusions: These findings redefine the CCL2-CCR2 axis as a T-cell-mediated tumor-suppressive pathway in BCa and support rCCL2-based therapy as a strategy to enhance immune infiltration and improve outcomes in treatment-resistant BCa.<\/jats:p>","DOI":"10.3390\/cancers18142267","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:05:07Z","timestamp":1784163907000},"page":"2267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling the Paradoxical Tumor-Suppressive Role of CCL2\/CCR2 in Bladder Cancer: A Novel Immunotherapeutic Strategy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1974-6075","authenticated-orcid":false,"given":"Neelam","family":"Mukherjee","sequence":"first","affiliation":[{"name":"Department of Urology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5852-6484","authenticated-orcid":false,"given":"Niannian","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-7164","authenticated-orcid":false,"given":"Zaineb","family":"Hassouneh","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Department of Microbiology, Immunology & Molecular Genetics, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Furman","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Gelfond","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onika D. V.","family":"Noel","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8590-4178","authenticated-orcid":false,"given":"Gisele","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-9003","authenticated-orcid":false,"given":"Chun-Liang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon L.","family":"Woldu","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-2723","authenticated-orcid":false,"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clin. Outcomes Res."},{"key":"ref_3","first-page":"103","article-title":"Role of immunotherapy in bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"36","author":"Mukherjee","year":"2018","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hatogai, K., and Sweis, R.F. (2020). The Tumor Microenvironment of Bladder Cancer, Springer. Advances in Experimental Medicine and Biology.","DOI":"10.1007\/978-3-030-59038-3_17"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Joseph, M., and Enting, D. (2019). Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01270"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","article-title":"Biomarkers for immunotherapy in bladder cancer: A moving target","volume":"5","author":"Aggen","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2008.06.017","article-title":"Chemotaxis, chemokine receptors and human disease","volume":"44","author":"Jin","year":"2008","journal-title":"Cytokine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0092-8674(83)90037-5","article-title":"Molecular cloning of gene sequences regulated by platelet-derived growth factor","volume":"33","author":"Cochran","year":"1983","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-5728(97)00208-7","article-title":"Expression of monocyte chemoattractant protein-1 and other \u03b2-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions","volume":"84","author":"Simpson","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ijc.2910450436","article-title":"A chemoattractant expressed in human sarcoma cells (tumor-derived chemotactic factor, TDCF) is identical to monocyte chemoattractant protein-1\/monocyte chemotactic and activating factor (MCP-1\/MCAF)","volume":"45","author":"Bottazzi","year":"1990","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1359-6101(99)00005-2","article-title":"The MCP\/eotaxin subfamily of CC chemokines","volume":"10","author":"Opdenakker","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D","article-title":"Chemokines induce migrational responses in human breast carcinoma cell lines","volume":"71","author":"Youngs","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2006.12.012","article-title":"CCL2\/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers","volume":"252","author":"Huang","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.celrep.2015.06.024","article-title":"CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function","volume":"12","author":"Chun","year":"2015","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/33340","article-title":"Chemokines and leukocyte traffic","volume":"392","author":"Baggiolini","year":"1998","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/187152807780832265","article-title":"MCP-1\/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy","volume":"6","author":"Xia","year":"2007","journal-title":"Inflamm. Allergy-Drug Targets"},{"key":"ref_19","first-page":"3282","article-title":"Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer","volume":"6","author":"Ueno","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.20141836","article-title":"CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages","volume":"212","author":"Kitamura","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/0008-5472.CAN-16-2310","article-title":"Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res."},{"key":"ref_22","first-page":"308","article-title":"Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-\u03baB Activity","volume":"6","author":"Lindholm","year":"2015","journal-title":"J. Clin. Cell Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41419-020-03111-7","article-title":"Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer","volume":"11","author":"Feng","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1084\/jem.20101956","article-title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells","volume":"208","author":"Molon","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e25474","DOI":"10.4161\/onci.25474","article-title":"A role for CCL2 in both tumor progression and immunosurveillance","volume":"2","author":"Li","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/eji.200526208","article-title":"Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4","volume":"36","author":"Zhang","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lavender, N., Yang, J., Chen, S.C., Sai, J., Johnson, C.A., Owens, P., Ayers, G.D., and Richmond, A. (2017). The Yin\/Yan of CCL2: A minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3074-2"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cyto.2012.04.017","article-title":"Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells","volume":"59","author":"Chiu","year":"2012","journal-title":"Cytokine"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Eckstein, M., Epple, E., Jung, R., Weigelt, K., Lieb, V., Sikic, D., Stohr, R., Geppert, C., Weyerer, V., and Bertz, S. (2020). CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage. Cancers, 12.","DOI":"10.3390\/cancers12051253"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1158\/2326-6066.CIR-21-0285","article-title":"\u03b3\u03b4 T Cells Support Antigen-Specific \u03b1\u03b2 T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer","volume":"9","author":"Ji","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e71150","DOI":"10.1002\/cam4.71150","article-title":"A Double-Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for Cancer Immunology Research","volume":"14","author":"Ji","year":"2025","journal-title":"Cancer Med."},{"key":"ref_34","unstructured":"Korac-Prlic, J., Degoricija, M., Vilovic, K., Vujevic, S., and Terzic, J. (2021). BBN-Driven Urinary Bladder Cancer Mouse Model, Elsevier. Methods in Cell Biology."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-022-03236-y","article-title":"Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer","volume":"72","author":"Ji","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/2326-6066.CIR-18-0336","article-title":"Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer","volume":"7","author":"Svatek","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1038\/s41598-020-64755-1","article-title":"Atypical chemokine receptor ACKR2-V41A has decreased CCL2 binding, scavenging, and activation, supporting sustained inflammation and increased Alzheimer\u2019s disease risk","volume":"10","author":"Murcia","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Adekoya, T.O., Smith, N., Kothari, P., Dacanay, M.A., Li, Y., and Richardson, R.M. (2024). CXCR1 Expression in MDA-PCa-2b Cell Upregulates ITM2A to Inhibit Tumor Growth. Cancers, 16.","DOI":"10.3390\/cancers16244138"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Luo, W., Wang, Y., He, S., Zhao, S., Zhou, Y., and Ai, L. (2026). Eccentric treadmill training and skeletal muscle immunometabolic responses in HFD-induced insulin resistance. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1757925"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hassouneh, Z., Noel, O.D.V., Ji, N., Kim, M.E., Svatek, J., Svatek, R.S., Risinger, A.L., and Mukherjee, N. (2024). Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer. Cancers, 16.","DOI":"10.3390\/cancers16223875"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1614857","DOI":"10.1080\/2162402X.2019.1614857","article-title":"Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: A translational clinical trial","volume":"8","author":"Ji","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_43","unstructured":"(2024, June 03). NIH National Cancer Institute, Available online: http:\/\/cancergenome.nih.gov\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"36492","DOI":"10.18632\/oncotarget.26362","article-title":"Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer","volume":"9","author":"Mukherjee","year":"2018","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1158\/1078-0432.CCR-14-1781","article-title":"Sequential intravesical mitomycin plus Bacillus Calmette-Guerin for non-muscle-invasive urothelial bladder carcinoma: Translational and phase I clinical trial","volume":"21","author":"Svatek","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12307-010-0052-5","article-title":"Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer","volume":"4","author":"Erreni","year":"2011","journal-title":"Cancer Microenviron."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhang, J., Patel, L., and Pienta, K.J. (2010). Targeting Chemokine (C-C Motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic, Elsevier. Progress in Molecular Biology and Translational Science.","DOI":"10.1016\/B978-0-12-385071-3.00003-4"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/0008-5472.CAN-11-1261","article-title":"Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway","volume":"71","author":"Daurkin","year":"2011","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.mrgentox.2011.11.015","article-title":"Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis","volume":"742","author":"He","year":"2012","journal-title":"Mutat. Res.\/Genet. Toxicol. Environ. Mutagen."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12967-019-02146-5","article-title":"The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice","volume":"17","author":"Degoricija","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Jin, J., Lin, J., Xu, A., Lou, J., Qian, C., Li, X., Wang, Y., Yu, W., and Tao, H. (2021). CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.722916"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jbo.2018.01.002","article-title":"Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer","volume":"11","author":"Wang","year":"2018","journal-title":"J. Bone Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1464-410x.1998.00675.x","article-title":"Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer","volume":"82","author":"Amann","year":"1998","journal-title":"Br. J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1038\/s41467-018-06152-x","article-title":"LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_57","first-page":"7451","article-title":"The CC chemokine MCP-1\/CCL2 in pancreatic cancer progression: Regulation of expression and potential mechanisms of antimalignant activity","volume":"63","author":"Monti","year":"2003","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/ijc.28867","article-title":"High coexpression of CCL2 and CX3CL1 is gender-specifically associated with good prognosis in soft tissue sarcoma patients","volume":"135","author":"Kehlen","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-012-1361-y","article-title":"Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance","volume":"62","author":"Zhang","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/14796694.2024.2363744","article-title":"N-803 Plus BCG Treatment for BCG-Naive or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review","volume":"20","author":"Chamie","year":"2024","journal-title":"Future Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Narayan, V.M., Meeks, J.J., Jakobsen, J.S., Shore, N.D., Sant, G.R., and Konety, B.R. (2024). Mechanism of action of nadofaragene firadenovec-vncg. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1359725"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guerin Failure in Patients with Non-muscle-invasive Bladder Cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Mancini, M., Righetto, M., and Noessner, E. (2021). Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. Cancers, 13.","DOI":"10.3390\/cancers13236016"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:11:31Z","timestamp":1784164291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":63,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142267"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142267","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}